MA-PRECISELY
14.12.2022 15:02:06 CET | Business Wire | Press release
Precisely, the global leader in data integrity, today announced the regional expansion of its unique location identifier, the PreciselyID, for its World Points of Interest (POI) data offering. Points of interest located in the US, Canada, Belgium, Luxembourg, the Netherlands, United Kingdom, Ireland, France, Sweden, and Singapore now benefit from accurate, standardized, and meaningful data – allowing businesses to streamline location-based decision-making across multiple regions of operation.
Disruption from the pandemic and other world events has had a lasting impact on many aspects of day-to-day life, including shopping habits, work location, and travel behaviors – making it even more important for businesses to be able to access accurate and current data on points of interest.
But keeping POI data fresh is no small feat, even for companies such as Google, who recently revealed that it removed seven million fake business profiles and prevented 12 million from being created throughout 2021 alone. Standardizing POI data is just as difficult; differences in address standards, language, character variations, or a lack of accurate address data, make it challenging for companies to effectively operationalize data from multiple regions.
Unlike other address identifiers on the market that associate a business name to an address, the PreciselyID is appended to both the location’s coordinates and the address and will remain constant over time. If a business closes and a new one opens in the same location, Precisely processes this change so that the PreciselyID will reflect the attributes for the new point of interest. As a result, businesses that use addresses as a primary data input will always have access to the most accurate data about any given location, enabling insights without needing geospatial tools or specialized skillsets.
“Businesses today need reliable answers about the world around them. If a clothing boutique closes, and the location becomes a coffee shop, it has an impact on the level of traffic, and types of shoppers, workers, and visitors to that area,” said Dan Adams, SVP – Data and Operations, at Precisely. “That’s why we associate the PreciselyID with an address and location, so our customers always have access to accurate, verified, and standardized data for detailed insights that matter to their business.”
POIs enabled with the PreciselyID have been cleansed, standardized, and verified by Precisely’s best-in-class geo addressing. As a result, organizations can quickly enrich records with accurate data while saving processing time and simplifying complex geospatial analysis. With access to a portfolio of over 400 datasets containing more than 9,000 attributes, Precisely customers can increase the accuracy, usability, and overall value of their business data and build context for faster, more confident decisions.
The regional expansion unlocks new capabilities for a wide variety of industries, including:
- Retail – Leveraging location insights for site selection and management, locating competition and demand to identify opportunities for new stores or consolidation
- Financial Services - Validating merchant data and achieving a 360-degree view of the changing landscape they operate in
- Insurance – Helping to understand adjacent risk – including whether a property is located near to a high-risk building, such as a chemical plant
- Telecommunications – Obtaining a full view into the places where people congregate, supporting telcos with their goal of providing high levels of coverage and keeping customers connected
- Public Sector – Understanding where people work, shop, and spend their leisure time, enhancing planning for public transport networks, emergency services, and planning
Precisely expects further expansion, with support for more countries added in the future. Learn more about how to seamlessly connect addresses, properties, and POI data with the PreciselyID here.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
